Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates : vimarsana.com

31.05.2023 - –   TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells –   TransCon IL-2 β/γ administered every 3 weeks was ... Seite 1

Related Keywords

Copenhagen , Køavn , Denmark , Ascendis Pharma , Jan Mikkelsen , Stina Singel , Webcast Of Ascendi Oncology Program , Company Oncology , Head Of Clinical Development , Ascendi Oncology Program Update , Executive Vice President , Clinical Development ,